Trade Benitec Biopharma Inc. - BNTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2344 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 11.8778 |
| Open | 11.5278 |
| 1-Year Change | 126.8% |
| Day's Range | 11.5278 - 13.0178 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 11.8778 | -0.3500 | -2.86% | 12.2278 | 12.8778 | 11.5578 |
| Mar 31, 2025 | 12.9778 | 0.1100 | 0.85% | 12.8678 | 13.3378 | 11.6478 |
| Mar 28, 2025 | 13.2578 | -0.0700 | -0.53% | 13.3278 | 13.7778 | 13.1578 |
| Mar 27, 2025 | 13.5578 | -0.4300 | -3.07% | 13.9878 | 14.1778 | 12.8778 |
| Mar 26, 2025 | 13.9878 | 0.2600 | 1.89% | 13.7278 | 14.5578 | 13.7278 |
| Mar 25, 2025 | 14.3078 | 0.1800 | 1.27% | 14.1278 | 14.9778 | 13.7878 |
| Mar 24, 2025 | 14.0878 | -0.8900 | -5.94% | 14.9778 | 16.0778 | 14.0278 |
| Mar 21, 2025 | 16.1278 | 0.4000 | 2.54% | 15.7278 | 16.5278 | 15.7278 |
| Mar 20, 2025 | 16.5878 | 1.2500 | 8.15% | 15.3378 | 16.6978 | 15.2678 |
| Mar 19, 2025 | 15.4378 | -0.0100 | -0.06% | 15.4478 | 15.7278 | 14.8178 |
| Mar 18, 2025 | 15.2078 | 0.1700 | 1.13% | 15.0378 | 15.3878 | 14.1878 |
| Mar 17, 2025 | 15.1678 | 0.1900 | 1.27% | 14.9778 | 15.7678 | 14.4478 |
| Mar 14, 2025 | 14.9478 | 0.1700 | 1.15% | 14.7778 | 15.0778 | 14.4478 |
| Mar 13, 2025 | 14.6778 | 0.5000 | 3.53% | 14.1778 | 14.7978 | 13.9778 |
| Mar 12, 2025 | 14.2978 | 1.4200 | 11.03% | 12.8778 | 14.5278 | 12.5678 |
| Mar 11, 2025 | 13.1078 | 1.8500 | 16.43% | 11.2578 | 13.2978 | 11.2578 |
| Mar 10, 2025 | 12.4678 | 0.2000 | 1.63% | 12.2678 | 12.8678 | 11.7778 |
| Mar 7, 2025 | 12.6578 | 0.7700 | 6.48% | 11.8878 | 12.9378 | 11.8878 |
| Mar 6, 2025 | 12.7378 | 1.9700 | 18.30% | 10.7678 | 12.8478 | 10.7678 |
| Mar 5, 2025 | 12.0278 | 0.5500 | 4.79% | 11.4778 | 12.3178 | 11.1178 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Benitec Biopharma Inc. Company profile
About Benitec Biopharma Inc
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Financial summary
BRIEF: For the six months ended 31 December 2021, Benitec Biopharma Inc revenues decreased 55% to $25K. Net loss increased 65% to $9.9M. Revenues reflect Licensing revenue segment decrease from $56K to $0K. Higher net loss reflects Research and development - Balancing val increase from $1.9M to $5.8M (expense), Stock-based Compensation in SGA increase from $105K to $349K (expense).
Equity composition
FY'05 is being restated for change in reporting GAAP to IFRS.04/2009, Rights Issue, 1 new share for every 3.142 shares held @ AUD .03 (Factor:1.000000). 04/2011, Rights Issue, 4 new shares for every 5 shares held @ AUD 0.02 (Factor:1.235330). 07/2013, 1-for-25 Reverse Stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
3940 Trust Way
HAYWARD
CALIFORNIA 94545
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com